Cell cycle progresses by the activation of cyclin and cdk complexes. They act as check points and regulate the transition of cell cycle from one phase to another. Cdk2 inhibitors decrease the kinase activities by blocking the transition from G1 to S phases. In this article, we present a review on purine based cdk2 inhibitors. The review covers in great detail the different structures and the effects on cdk2 inhibition by various substitutions. The substitutions that most greatly influence the orientation and binding towards the ATP binding site are discussed and the effects of several substituents that explored the active site region of cdk2 with bound inhibitor has provided a rationale to review four relatively new families of purine based cdk2 inhibitors such as imidazo[1,2-a]pyridines, imidazo[1,2-b]pyridazines, 1H-pyrazolo [3,4-b]pyridines and O 6 -substituted guanines, respectively. The orientation and hydrogen bond interactions of analogues with Leu83, Asp86 and Lys33 residues influence the binding and the major features responsible for effective cdk2 inhibitor discovery and design are presented.
Introduction
Cell proliferation is a consequence of positive signals which promote cell division and negative signals which suppress the process. Key factors in this signaling cascade are a series of cyclin dependent kinases (cdks) 1 . It has been shown that they are also required for replication of viruses that replicate only in dividing cells, such as adeno-and papillomaviruses as well as in nondividing cells, such as HIV-1 and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) 2 .
Cyclin-dependent kinases are a family of serine/threonine kinases which play a crucial role in cell cycle control 3 and are involved in diverse cellular processes, in regulation of cell division (cdks1, 2, 3, 4, 6 and 7), transcription (cdks7, 8 and 9) or maintenance of the structure of the cytoskeleton (cdk5) 2 .
Cyclin dependent kinases control the cell cycle progression operating at the transition from G 2 to M, G 1 to S phases, and progression through S phase, regulated by a complex set of mechanisms, including the presence of activating cyclins, regulatory phosphorylations, and endogenous cdk inhibitors at checkpoints 4 . Cell cycle progresses by the activation of Cyclin and cdk complexes 5 . These cyclins and cdks function as check points regulating the transition from one phase of cell cycle to another. Structural studies have explored the active and inactive states of cdk2. Monomeric form was inactive, while association of Cyclin A with cdk2 and Thr160 phosphorylation results active cdk2 6 . Active complex phosphorylate and inactivate members of the retinoblastoma protein (Rb) family that are negative regulators of G1 and S-phase progression, leading to induction of E2F-regulated gene expression and cell proliferation 7 . Cdk inhibitors decrease the kinase activities of the cyclin/cdk complexes, blocking the transition from G1 to S phases 8 . Activation of cdk2 results in rotation of N-and C-terminal domains leading to a slight widening of ATP cleft 9 . The movement of PSTAIRE helix and Glu51 and the subsequent reorganization leads to reshaping of the phosphate-binding site 10, 11 .
Following the discovery of olomoucine and roscovitine ( Figure 1 ) as selective ATP competitive cdk2 inhibitors, much effort has been devoted to find more specific and potent inhibitors because kinases within the cell share a high degree of sequence similarity at the active site. X-ray crystallographic analysis of a substantial number of cdk2/inhibitor complexes has elaborated the diverse binding modes of different inhibitors in atomic detail 3 . Several types of and others [21] [22] [23] . Based on the studies that explored the active site region of cdk2 with bound inhibitor, and the role of cdk2 in cell cycle progression and proliferation, cdk2 acts as a potential therapeutic target in several proliferative diseases, including cancer 11 
Purines
Cytokinin derived purine analogues yielded the first cdk-selective protein kinase inhibitors 24 .
The first cdk inhibitor discovered was dimethylaminopurine 25 shown to inhibit cdk1 activity (IC 50 : 120 µM). A derivative, isopentenyladenine was somewhat more selective than dimethylaminopurine [26] . Later on, a moderately potent cdk2 inhibitor, olomoucine 1 15 was developed followed by roscovitine 2 16, [27] [28] [29] and bohemine 3 30 with improved inhibition ( Figure   1 ). The purvalanols (4a and 4b) with 6-anilino purine substituents are the most potent cdk2 inhibitors 31 .
2-(1R-isopropyl-2-hydroxyethylamino)-6-(3-chloro-4-carboxyphenylamino)-9-isopropylpurine (purvalanol B), has an IC 50 of 6 nM against cdk2-cyclin A complex, which corresponds to a 1000-fold increase over olomoucine and a 30-fold increase over flavopiridol 32 .
Imidazo[1,2-a]pyridines
The importance of imidazo[1,2-a]pyridine 33, 34 group and SAR were reported 35, 36 to investigate the binding site selectivity between cdk2 and cdk4 ( Figure 2 ). The affinity of compound 5 (IC 50 : 2.9 µM) with ATP binding site residues, depicted in Figure 
Effect of sulfonamide substitution
Structural studies showed that the aniline group substitution with sulfonamide was beneficial for cdk2 activity 37 . 
Effect of electron-withdrawing and electron-donating groups on aryl ring (R 3 ).

Imidazo[1,2-b]pyridazines
The sulfonamide substituted imidazo[1,2-a]pyridine core structure 37 
Effect of 4-position substitution
Replacement of oxygen with either nitrogen or sulfur at position 4 (32, 33; IC 50 : 4.4µM, >25µM) resulted in a significant loss of cdk2 activity. Straight chain, branched and cyclic alkoxy groups are tolerated as they extend into the space occupied by the ribose of ATP without any specific contacts with the protein. Polar substituents like hydroxyl and dimethylamino resulted in loss of activity 41 . An ortho fluoro substitution on 5-keto phenyl ring represents a key for potent inhibitory activity 42 . The 2,4,6-trimethylphenyl analogue, 36 (IC 50 : >1.0µM) resulted as a poor cdk2 inhibitor in contrast with 2,6-difluoro-4-methyl analogue, 37 (IC 50 : 0.009µM). 43 , (Figure 8) homologous to cdk2
Effect of 5-position substitution
Effect of 6-position substitution GSK-3 class of inhibitors, 6-aryl-pyrazolo[3,4-b]pyridines
inhibitors were tested for specificity as they both share a high degree of similarity. Substitution at position 6 with small heterocycles, such as 2-pyrrolyl, 2-furanyl and 2-thienyl exhibited greater potency than the corresponding phenyl analogue. at 100 µM and 49 ± 14 at 10 µM). This might be due to the substituents unable to form favorable hydrogen bonds within the ribose binding domain. SAR studies suggest that a broad range of substituents are tolerated at the O 6 -position, but none resulted in appreciable activity or specificity as seen with NU2058, which suggests that the hydrogen bonds formed by the substituents within the ribose pocket contributed greatly towards potency and selectivity. X-ray structure of NU2058 bound to monomeric cdk2 revealed that it forms a triplet of hydrogen bonds within the ATP binding site between residues in the hinge region of cdk2 and the NH 2 , N3, and N9 nitrogen atoms of the inhibitor 43 . Comparison of structures ( Figure 9 ) of NU2058 (pdb code: 1e1v) and olomoucine (pdb code: 1w0x) bound to monomeric cdk2 revealed that NU2058 represents a different class of inhibitor to olomoucine [15] (IC 50 : 7 µM) as the two compounds bind in different orientations 45 . Extending this observation, SAR studies for a series of N 2 -substituted O 6 -cyclohexylmethylguanine derivatives 46, 47 
Conclusions
A number of compounds with diverse substituents explored the potential active site region of cdk2 resulted in micromolar inhibition. The orientation and hydrogen bond interactions of analogues with Leu83, Asp86 and Lys33 greatly influence the binding for purine based cdk2 inhibitors and the major features responsible for effective cdk2 inhibitor discovery and design for four families are: -presence of hydrophobic phenylamino moiety on imidazo[1,2-a]pyridines.
-presence of 4-sulfonamide substituent on the phenylamino moiety of imidazo [1,2-b] pyridazines to reduce lipophilicity -4-, 5-and 6-position heterocycle substitutions are well tolerated on pyrazolo [3,4- 
